New hope for hepatitis b: experimental drug LW231 enters human trials
NCT ID NCT07179575
First seen Oct 31, 2025 · Last updated May 12, 2026 · Updated 16 times
Summary
This study tests a new medicine called LW231 in people with chronic hepatitis B. The goal is to see if it is safe and can lower the amount of virus in the blood. Some participants will get LW231 alone, and others will get it together with standard antiviral pills. The study involves about 270 adults and is currently recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HBV INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital, Zhejiang University School of Medicine
NOT_YET_RECRUITINGHangzhou, China
Conditions
Explore the condition pages connected to this study.